These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

588 related items for PubMed ID: 20346218

  • 1. Clinical features and survival analysis of different subtypes of patients with breast cancer brain metastases.
    Bai B, Yuan ZY, Liu DG, Teng XY, Wang SS.
    Chin J Cancer; 2010 Apr; 29(4):413-9. PubMed ID: 20346218
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM, Zhang BN, Xuan LX, Zhao P.
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [Abstract] [Full Text] [Related]

  • 5. [Breast cancer brain metastases: clinical and prognostic characteristics of different biological subtypes].
    Zhang T, Li Q, Xu B, Zhang P, Yuan P, Ma F, Wang J, Fan Y.
    Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):697-702. PubMed ID: 25564062
    [Abstract] [Full Text] [Related]

  • 6. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, Liu XF, Yu ZH.
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [Abstract] [Full Text] [Related]

  • 7. Treatment and prognosis of breast cancer patients with brain metastases according to intrinsic subtype.
    Kuba S, Ishida M, Nakamura Y, Yamanouchi K, Minami S, Taguchi K, Eguchi S, Ohno S.
    Jpn J Clin Oncol; 2014 Nov; 44(11):1025-31. PubMed ID: 25156682
    [Abstract] [Full Text] [Related]

  • 8. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P, Xu BH, Ma F, Li Q, Yuan P, Wang JY, Zhang P.
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [Abstract] [Full Text] [Related]

  • 9. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.
    Niikura N, Hayashi N, Masuda N, Takashima S, Nakamura R, Watanabe K, Kanbayashi C, Ishida M, Hozumi Y, Tsuneizumi M, Kondo N, Naito Y, Honda Y, Matsui A, Fujisawa T, Oshitanai R, Yasojima H, Tokuda Y, Saji S, Iwata H.
    Breast Cancer Res Treat; 2014 Aug; 147(1):103-12. PubMed ID: 25106661
    [Abstract] [Full Text] [Related]

  • 10. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
    Miller JA, Kotecha R, Ahluwalia MS, Mohammadi AM, Chao ST, Barnett GH, Murphy ES, Vogelbaum MA, Angelov L, Peereboom DM, Suh JH.
    Cancer; 2017 Jun 15; 123(12):2283-2293. PubMed ID: 28192598
    [Abstract] [Full Text] [Related]

  • 11. [Clinical characteristics and prognosis of different subtypes of breast cancer].
    Yuan ZY, Wang SS, Zhu MQ, Zheng L, Luo WB, Zhou ZM, Guan ZZ.
    Zhonghua Zhong Liu Za Zhi; 2008 Jun 15; 30(6):456-61. PubMed ID: 19024523
    [Abstract] [Full Text] [Related]

  • 12. Molecular breast cancer subtypes and therapies in a public hospital of northeastern Brazil.
    de Macêdo Andrade AC, Ferreira Júnior CA, Dantas Guimarães B, Pessoa Barros AW, Sarmento de Almeida G, Weller M.
    BMC Womens Health; 2014 Sep 12; 14():110. PubMed ID: 25216732
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype.
    Alramadhan M, Ryu JM, Rayzah M, Nam SJ, Kim SW, Yu J, Lee SK, Bae SY, Park S, Paik HJ, Lee JE.
    Breast; 2016 Dec 12; 30():111-117. PubMed ID: 27697675
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of preoperative 18F-FDG PET/CT for breast cancer subtypes.
    Higuchi T, Nishimukai A, Ozawa H, Fujimoto Y, Yanai A, Miyagawa Y, Murase K, Imamura M, Takatsuka Y, Kitajima K, Fukushima K, Miyoshi Y.
    Breast; 2016 Dec 12; 30():5-12. PubMed ID: 27569020
    [Abstract] [Full Text] [Related]

  • 16. [Clinical analysis of 67 patients with brain metastases from breast cancer].
    He J, Feng FY, Xing PY, Wang XY, Zhang P.
    Ai Zheng; 2005 Dec 12; 24(12):1527-30. PubMed ID: 16351807
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype.
    Arvold ND, Oh KS, Niemierko A, Taghian AG, Lin NU, Abi-Raad RF, Sreedhara M, Harris JR, Alexander BM.
    Breast Cancer Res Treat; 2012 Nov 12; 136(1):153-60. PubMed ID: 22968656
    [Abstract] [Full Text] [Related]

  • 20. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
    Braccini AL, Azria D, Thezenas S, Romieu G, Ferrero JM, Jacot W.
    Breast; 2013 Oct 12; 22(5):993-8. PubMed ID: 23831232
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.